Baird raised the firm’s price target on Exact Sciences (EXAS) to $88 from $72 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results and raised its revenue outlook.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $90 from $74 at TD Cowen
- Exact Sciences price target raised to $85 from $75 at BTIG
- Exact Sciences price target raised to $80 from $67 at Stifel
- Exact Sciences: Strong Growth Potential and Strategic Initiatives Justify Buy Rating
- Exact Sciences price target raised to $77 from $65 at Barclays